Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the…
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon…
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for…
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant….
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE)…
Final study results show Grace Breeding’s NFT, an alternative to reduce urea, was superior or…
Topline results expected in first half of 2023 Trial sites open in Australia and United…
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”),…
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18…
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in…
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”),…
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics…
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder…
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of…
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin…
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan….
WALTHAM, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) — Infinidat, a leading provider of enterprise storage…